Cite
HARVARD Citation
Bahl, A. et al. (2022). Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer. Breast. pp. 69-76. [Online].